
|Videos|September 2, 2022
Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy
Author(s)Sunandana Chandra, MD, MS
An overview of the treatment options for patients with mUM who ineligible for treatment with tebentafusp.
Advertisement
Episodes in this series

Advertisement
Related to this article

Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.

Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.

Most people with pancreatic cancer lose weight they didn't mean to. Here is how weight loss from poor digestion differs from cachexia, and what enzymes, eating strategies and appetite medicines can do.

Dr. Rebecca Dent explains how Datroway kept brain metastases in check longer than chemotherapy in triple-negative breast cancer, and what patients should know.

In a study of 8,259 rural Medicare patients with advanced non-small cell lung cancer diagnosed from 2014 to 2019, only 35.9% had tumor gene testing, and those who were tested were more likely to get targeted therapy.

Among U.S. adults with a history of cancer, 45.8% reported drinking alcohol in the past 30 days in both 2016 and 2024, while drinking declined among adults without cancer, according to a study in Cancer Causes & Control of nearly 4 million adults.

Dr. Matteo Lambertini explains how Lynkuet reduced hot flashes in people on endocrine therapy for breast cancer, no matter when their treatment began.
Advertisement
Advertisement
Trending on CURE
1
What Is a Whipple Procedure? Pancreatic Cancer Surgery Explained
2
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
3
Weight Loss With Pancreatic Cancer: Why It Happens and What Helps
4
Glioblastoma Patients Can Request Genomic Testing on Their Tumor Tissue
5

